Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00939809 · ClinicalTrials.gov registry record · Phase 2

A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

A Phase 2 study of Recurrent Ovarian Carcinoma and Primary Peritoneal Carcinoma, sponsored by Gynecologic Oncology Group.

Completed
Registry status
Phase 2
Development phase
31
Enrollment target
16
Study locations

NCT00939809 is a Phase 2 study of Recurrent Ovarian Carcinoma and Primary Peritoneal Carcinoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 31 participants, below the 123-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (75% lower). The trial reports 16 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00939809, a Phase 2 study of Recurrent Ovarian Carcinoma and Primary Peritoneal Carcinoma, has completed, sponsored by Gynecologic Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
31 participants
Enrollment target
16
Study locations

Study Summary

This phase II trial is studying the side effects and how well A6 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. A6 may stop the growth of tumor cells by blocking blood flow to the tumor.

Conditions Studied

Recurrent Ovarian Carcinoma Primary Peritoneal Carcinoma Ovarian Endometrioid Adenocarcinoma Fallopian Tube Carcinoma Ovarian Brenner Tumor Ovarian Mucinous Cystadenocarcinoma Ovarian Clear Cell Cystadenocarcinoma Ovarian Serous Cystadenocarcinoma Malignant Ovarian Mixed Epithelial Tumor Undifferentiated Ovarian Carcinoma

Interventions

  • OTHER Laboratory Biomarker Analysis
  • BIOLOGICAL Urokinase-Derived Peptide A6

Study Locations (16)

Ohio

  • Case Western Reserve University - Cleveland
  • MetroHealth Medical Center - Cleveland
  • Cleveland Clinic Cancer Center/Fairview Hospital - Cleveland
  • Riverside Methodist Hospital - Columbus
  • Hillcrest Hospital Cancer Center - Mayfield Heights

Pennsylvania

  • Abington Memorial Hospital - Abington
  • Magee-Womens Hospital of UPMC - Pittsburgh

Georgia

  • Georgia Regents University Medical Center - Augusta

Iowa

  • University of Iowa Hospitals and Clinics - Iowa City

Nebraska

  • Nebraska Methodist Hospital - Omaha

New York

  • Stony Brook University Medical Center - Stony Brook

Oklahoma

  • University of Oklahoma Health Sciences Center - Oklahoma City

Rhode Island

  • Women and Infants Hospital - Providence

Trial Details

FieldValue
Enrollment Target 31 participants
Start Date 2009-07
Phase Phase 2

Sponsor

Gynecologic Oncology Group

154 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00939809

The ClinicalTrials.gov registry entry for NCT00939809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 123-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (75% lower). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.

The record links to 10 conditions, with Recurrent Ovarian Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT00939809 reports 16 study locations spanning 11 distinct geographic areas - top geographies include Ohio, Pennsylvania, Georgia.

Frequently Asked Questions

What is clinical trial NCT00939809 about?

NCT00939809 is a clinical study titled "A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". This phase II trial is studying the side effects and how well A6 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. A6 may stop the growth of tumor cells by blocking blood flow to the tumor.

What is the current status of trial NCT00939809?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2009-07.

What conditions does trial NCT00939809 study?

This clinical trial studies the following conditions: Recurrent Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Endometrioid Adenocarcinoma, Fallopian Tube Carcinoma, Ovarian Brenner Tumor.

What interventions are being tested in trial NCT00939809?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Urokinase-Derived Peptide A6 (BIOLOGICAL).

Who is sponsoring clinical trial NCT00939809?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00939809 being conducted?

This trial has 16 study locations across Georgia, Iowa, Nebraska, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Recurrent Ovarian Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Recurrent Ovarian Carcinoma

All registered trials for this condition

Primary Peritoneal Carcinoma

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.